Articles related to TRAUMATIC BRAIN INJURY (TBI)

Amantadine emerges as the pharmacologic agent with the most support for improving cognitive impairment after TBI, while cognitive rehabilitation interventions demonstrate substantial evidence for enhancing neurocognitive function and reducing functional limitations.

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.

The introduction of these new guidelines marks a significant advancement in our understanding and determination of brain death. An emphasis on standardization and accuracy, these guidelines could change how we approach this critical aspect of medical practice.

Learn more about this landmark case that underscores the critical importance of patient safety rules and proper care.

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.